ArticlePediatric investigation2025
Low-dose versus high-dose methylprednisolone for children with severe
Article in Pediatric investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- East Asia as a sentinel: risk-stratified corticosteroid therapy for paediatric macrolide-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Impact of early corticosteroid therapy on short-term pulmonary function and clinical outcomes in children with severeFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Although macrolides combined with glucocorticoid therapy have demonstrated efficacy in preventing long-term pulmonary lesions of severe Objective: To evaluate the effects of low- and high-dose methylprednisolone on the risk of long-term pulmonary lesions for children with severe MPP when combined with azithromycin. Methods: This randomized, parallel-controlled, multicenter clinical trial was conducted in mainland China and enrolled pediatric patients hospitalized with severe MPP. A total of 424 enrolled patients were randomized (allocation ratio of 1:1) to azithromycin combined with either a low-dose [2 mg/(kg·d)] or a high-dose [10 mg/(kg·d)] methylprednisolone treatment for 3 d followed by tapering over 12 d. The primary outcome was the incidence of composite adverse outcomes, including atelectasis, bronchiectasis, or bronchiolitis obliterans 6 months after treatment. Results: A total of 118 (27.8%) developed adverse pulmonary lesions at 6 months after treatment; 66 of 211 (31.3%) in the high-dose methylprednisolone group and 52 of 213 (24.4%) in the low-dose group, respectively. The risk ratio of long-term pulmonary lesions in a high-dose group to those in a low-dose group was 1.28 (95% confidence interval [95% CI]: 0.94-1.75). In addition, the risk of hypertension in the high-dose group (8.1%, 17 of 211) was higher than that in the low-dose group (1.4%, three of 213), with a risk ratio of 5.72 (95% CI: 1.70-19.23). Interpretation: Azithromycin combined with low-dose methylprednisolone demonstrates non-inferior efficacy in reducing pulmonary lesions at 6-month follow-up compared to combined with high-dose methylprednisolone while exhibiting a more favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.